Most likely
B+
Bull case
60%
Probability
Target price
$13.25
+1.2% vs current
CCRN
Cross Country HealthcareANasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3B
Base case
25%
Probability
Target price
$13.10
+0.1% vs current
B-
Bear case
15%
Probability
Target price
$9.75
-25.5% vs current
AI sentiment snapshot
Latest data as of 2026-05-09
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+45.7
Score
AI commentary
Post-earnings tone is best described as neutral-to-cautious. The most important new fact is the signed cash acquisition, not a major operating inflection. The stock’s May 7 anchor close of $13.09 versus the $13.25 offer suggests the market largely accepted the deal framing immediately. Available post-print analyst reaction appears limited and mostly transactional rather than fundamentally bullish, with at least one target reset to the deal price and downgrades to more neutral stances. Coverage remains thin, so absence of broader revision data should lower confidence rather than be read as positive confirmation.
RankAlpha Sentiment Codex - 2026-05-09
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-07catalystQ1 showed mixed operating stabilization, not a clean standalone re-rateMedium impact
Q1 2026 revenue was $241.1 million, above the prior $235 million-$240 million guide, with Travel Nurse and Allied up 7% sequentially and four new MSP/VMS wins, but adjusted EBITDA was only $3.9 million and below the prior $4.0 million-$5.0 million range. The quarter supports a stabilization narrative, yet not enough to overpower the merger-arbitrage setup [#8-K-2026-05-07].
2026-09-30eventKnox Lane cash merger now dominates the setupMedium impact
Cross Country entered a merger agreement on May 6, 2026 under which holders would receive $13.25 per share in cash. Closing requires majority stockholder approval and HSR-related clearance, but the merger is not subject to a financing condition; the company also disclosed that securities would be delisted if the merger closes [#8-K-2026-05-06] [#10-Q-2026-05-08].
2026-12-31catalystIf the deal breaks, cash and buybacks help, but the core business still needs proofHigh impact
As of March 31, 2026, Cross Country had $105.6 million of cash, no debt drawn, and repurchased 657,653 shares in Q1 for $5.8 million, leaving $28.1 million authorized. That balance-sheet support matters if the merger fails, but the underlying business still posted an 18% year-over-year revenue decline and thin EBITDA, so any standalone upside case remains cautious [#10-Q-2026-05-08].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology